Capricor Therapeutics Class Action: What Investors Need to Know
Important Update for Capricor Therapeutics Investors
Background on the Case
Capricor Therapeutics, Inc. (NASDAQ: CAPR) finds itself in hot waters as investors have initiated a securities class action. This lawsuit targets investors who purchased shares between December 17, 2025, and July 26, 2026. Following the release of FDA briefing documents concerning the HOPE-3 trial, CAPR shares plummeted dramatically, resulting in significant monetary losses for investors.
Between July 24, 2026, and the following days, the stock price witnessed an astonishing decline from $19.70 to approximately $4.19. This translates to a staggering 78.7% drop in its value, equating to a loss of $15.08 per share for countless investors. The repercussions of this decline led to severe financial ramifications, with the stock plunging by $12.70 (64%) on July 27, 2026, followed by a further decrease of $2.38 (36%) on July 30, 2026. Clearly, the ability to recoup these losses is paramount for affected investors.
What Investors Can Do
As a result of the lawsuit, investors hold certain rights under federal securities law. Here’s what you need to know:
- - Eligibility: Investors who purchased CAPR stock within the specified period may be eligible to participate in the class action, regardless of whether they still hold their shares.
- - Deadline: Applications to be a lead plaintiff must be submitted by September 28, 2026. However, investors do not need to take immediate action to remain eligible as absent class members.
- - Legal Rights: Investors can seek the appointment as lead plaintiff, which allows for direct oversight of the case. They also have the right to recover losses whether shares were sold before or after the notable disclosures.
- - Calling for Action: Interested investors can contact Joseph E. Levi, Esq. at SueWallSt for a no-obligation review of their trading records. This service does not require upfront cost.
Key Allegations in the Case
The legal action stipulates that Capricor failed to disclose alterations made to the pre-specified statistical analysis plan related to the Phase 3 HOPE-3 trial. According to the claim, these changes were conducted without the FDA's approval, raising crucial questions about transparency and accountability. The FDA later characterized the analyses as
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.